Research Article

A Prognostic 14-Gene Expression Signature for Lung Adenocarcinoma: A Study Based on TCGA Data Mining

Jie Liu,1,2 Shiqiang Hou,3 Jinyi Wang,1 Zhengjun Chai,1 Xuan Hong,1 Tian Zhao,1 Zhengliang Sun,1 Liandi Bai,1 Hongyan Gao,1 Jing Gao,1 and Guohan Chen1
1Department of Thoracic Surgery, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China
2Research Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China
3Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China

Correspondence should be addressed to Guohan Chen; chenguohan0160@126.com

Received 30 September 2020; Revised 22 November 2020; Accepted 7 December 2020; Published 19 December 2020

Academic Editor: Bin Duan

Copyright © 2020 Jie Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Lung adenocarcinoma (LUAD), a major and fatal subtype of lung cancer, caused lots of mortalities and showed different outcomes in prognosis. This study was to assess key genes and to develop a prognostic signature for the patient therapy with LUAD. Method. RNA expression profile and clinical data from 522 LUAD patients were accessed and downloaded from the Cancer Genome Atlas (TCGA) database. Differentially expressed genes (DEGs) were extracted and analyzed between normal tissues and LUAD samples. Then, a 14-DEG signature was developed and identified for the survival prediction in LUAD patients by means of univariate and multivariate Cox regression analyses. The gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed to predict the potential biological functions and pathways of these DEGs. Results. Twenty-two out of 5924 DEGs in the TCGA dataset were screened and associated with the overall survival (OS) of LUAD patients. 14-DEGs were finally selected and included in our development and validation model by risk score analysis. The ROC analysis indicated that the specificity and sensitivity of this prognostic signature were high. Further functional enrichment analyses indicated that these DEGs might regulate genes that affect the function of release of sequestered calcium ion into cytosol and pathways that associated with vibrio cholerae infection. Conclusion. Our study developed a novel 14-DEG signature providing more efficient and persuasive prognostic information beyond conventional clinicopathological factors for survival prediction of LUAD patients.

1. Introduction

Lung cancer continues to be the leading cause of cancer-related mortality around the world [1], in which non-small-cell lung cancer (NSCLC) is the most often type, being mainly subdivided into adenocarcinoma (LUAD), squamous cell carcinomas (LUSC), and large cell carcinoma (LCC) [2, 3]. In the past decades, LUAD represents the major lung cancer population, increasingly accounting for approximately 40% of all lung cancers [4]. LUAD were characterized by distinct epidemiological, clinicopathological, and molecular properties [5]. Despite the improvements in diagnosis and therapy made during the past 30 years, the biomarkers for early detecting, prediction of high rate of relapse and mortality populations and the identification of target or immunological therapies for lung cancer patients are still unsatisfactory. Thus, identification of effective biomarkers for the prognosis of LUAD is critical for the diagnosis and treatment of LUAD patients.

Differentially expressed genes (DEGs) that regulated by gene transcription are implicated in diverse biological processes. Gene-expression profiling analysis made some progresses in predicting overall survival (OS) in NSCLC [1, 6, 7]. Mascaux et al. showed that immune activation and immune escape in tumor microenvironment (TME) occurred before lung cancer invasion [7]. With the importance of DEGs involved in cancer
research, the roles of DEGs as biomarkers and drivers of tumor oncogenesis and suppression have been identified. However, there are no definite and effective biomarkers in predicting the 5-year survival rate of LUAD patients, which bring great difficulty to clinical prognosis. Therefore, investigation in DEGs may be the solution to noninvasive biomarkers for LUAD.

Although several genes or long noncoding RNA expression signatures, including programmed death-ligand 1 (PD-L1), have been recently proposed for predicting the OS in NSCLC [6, 8–10], the prognostic value of an effective and new biomarker of gene profile is still limited. DEG signatures identification related to patient OS in standard clinical samples may promote the development of molecular drug subtypes and potential therapy targets. LUAD and LUSC exhibit distinction in the epidemiology, molecular characteristics, and prognosis [5]. Although several prognostic DEG signatures have been discovered for NSCLC [11, 12], few of these research identify and pinpoint the prognostic value of DEGs biomarkers for LUAD patients in a large cohort. Therefore, we focused on the DEG signature of LUAD not previously published.

In this study, we identified a 14-DEG signature as a predictor of survival risk of LUAD patients using a cohort of 522 cases from The Cancer Genome Atlas (TCGA) database. We employed a survival-associated risk score formula to identify a novel 14-DEG prognostic signature from the TCGA dataset of 522 LUAD patient samples. To show the conscientiousness of this signature, the specificity and sensitivity of our model were examined by the area under ROC curve (AUROC) analysis. A 14-DEG signature which could distinguish patients between good and poor survival was developed by means of Cox regression analysis and risk score model method. A higher area under curve (AUC) of the receiver operating characteristic (ROC) curve confirmed good sensitivity and specificity of the prognostic model, while multivariate Cox regression analysis and stratified analysis indicated the independence of predictive capacity of the 14-DEG prognostic signature. Besides, the functional enrichment analysis demonstrated that the 14-DEG may be probably involved in the progression of LUAD through exerting their roles in LUAD-related function of release of sequestered calcium ion into cytosol and pathways that associated with vibrio cholerae infection. Therefore, our finding may provide insights into the predictive capacity of DEG signature elaborating LUAD.

2. Materials and Methods

2.1. The LUAD Patient Dataset. The RNA-Seq data set of patients with LUAD was downloaded from the TCGA database (https://cancergenome.nih.gov/), including clinical features. The patients with the following criteria were filtered: patients with complete information of RNA expression profiles and clinical factors (including age, gender, TNM stage, survival status, and survival time).

2.2. Differentially Expressed Gene Screening in LUAD. Raw gene-level counts were utilized in our analysis. All the data processing and normalization were performed and completed by using the Perl and R version 4.0.0. The gene expression profiling data of the 522 LUAD samples and 59 normal samples were downloaded from the TCGA database. The DEGs between normal and LUAD group were identified through the “edgeR” package from Bioconductor in R language [13]. $|\log 2FC| > 2$ and adjusted $p$ value < 0.01 were set as the threshold for screening the expression difference of DEGs.

2.3. Cox Regression Analysis. The RNA-seq expression values were transformed in log2 format to normalize the data. Univariate Cox regression analysis using the “Survival” R package was performed to clarify the association between DEG expression and patient survival. The DEGs ($p$ value < 1.0e-06) from the univariate analysis were considered as potential candidate DEGs associated with OS. To determine the independent predictive capacity of the 14-DEG signature for LUAD patients, a stepwise multivariate Cox regression analysis was executed to identify the predictive model with the best explanatory and informative efficacy.

2.4. Risk Score and ROC Curve. A mathematical formula $(\text{Riskscore} = \sum_{i=1}^{N} (\text{Exp}(i) \cdot \text{coef}(i)))$ was developed to predict the risk score for each patient based on the multivariate Cox regression analysis. In accordance with our risk scoring system, patients were classified into high-risk and low-risk groups according to the median risk score. A Kaplan–Meier overall survival curve of the different stages was plotted, and the hazard ratio was calculated. Subsequently, the log-rank test was utilized to determine the survival differences between high-risk and low-risk groups. The sensitivity and specificity of the DEG prognostic model to predict clinical outcome were evaluated by calculating the area under curve (AUC) of the receiver operating characteristic (ROC) curve in the R package of “survival ROC” [14].

2.5. Differential Analysis of Scores and DEG Expression with Clinicopathological Stages. The clinicopathological characteristics data corresponding to the LUAD samples were downloaded from TCGA. The independence of the RiskScore from the clinical parameters, such as age, gender, and tumor stage, was determined, and the statistical analysis was performed by Kruskal–Wallis rank sum test or log-rank test as the significance test. In addition, the differential expression of the DEGs between distinct clinicopathologic stages was analyzed and plotted.

2.6. Function Enrichment Analysis. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was carried out for DEGs with the aid of clusterProfiler R package. Only terms with $p$ value < 0.05 were considered as significantly enriched in functions of prognostic DEGs and KEGG pathway analysis.

3. Results

3.1. Patient Characteristics. The whole construction process in our research was showed in Figure 1. On basis of the defined criteria, a total of 522 LUAD patients with both
RNA-seq expression profiles and clinical data were downloaded from the TCGA. The clinical covariates of the patients in normal or LUAD group were showed in Table 1. 47.89 percent of 522 LUAD patients was no more than and 52.11 percent was more than 65 years old. The female accounted for 53.64% and the male 46.36% in these patients. Of the 522 patients, 280 were classified as stage I, 130 as stage II, while 86 were labeled with stage III and 26 with stage IV disease. The survival time of 522 LUAD patients was $902.51 \pm 892.15$ days.

### 3.2. Differentially Expressed Genes in LUAD Patients

According to the defined criteria, a total of 5924 DEGs (including 5147 upregulated and 777 downregulated) were extracted between LUAD and normal samples (Figure 2(a)). The results of unsupervised hierarchical cluster analysis in Figure 2(b) showed that the LUAD samples could be clearly distinguished from the normal controls with the expression of DEGs.

A total of 5924 DEGs were screened to be differentially expressed between LUAD and normal tissues and were used for survival analysis. To identify the DEGs which were related to patient survival in LUAD, univariate Cox regression analysis for all DEG expression data was assessed. With the significance level threshold of $1.0 \times 10^{-6}$, a set of 22 DEGs was selected. These DEGs were utilized in stepwise multivariate Cox regression analysis, and finally, 14 DEGs (C1QTNF6, ERO1A, MELTF, ITGB1-DT, RGS20, FETUB, NTSR1, LINC02178, AC034223.2, LINC01312, AL353746.1, AC034223.1, DRAXINP1, and LINC02310) were identified as the gene signature.

### Table 1: Summary of LUAD patient clinical characteristics

| Covariates | Group | Patients (N = 522) |
|------------|-------|-------------------|
| Survival time | Alive | 334 | 63.98 |
| | Dead | 188 | 36.02 |
| | I | 280 | 53.64 |
| | II | 130 | 24.90 |
| | III | 86 | 16.48 |
| | IV | 26 | 4.98 |
| T stage | T1 | 172 | 32.95 |
| | T2 | 281 | 53.83 |
| | T3 | 47 | 9.00 |
| | T4 | 22 | 4.21 |
| | N0 | 342 | 65.52 |
| | N1 | 99 | 18.97 |
| | N2 | 75 | 14.37 |
| | N3 | 6 | 1.15 |
| | M0 | 496 | 95.02 |
| | M1 | 26 | 4.98 |
| | ≤65 | 250 | 47.89 |
| | >65 | 272 | 52.11 |
| Gender | Female | 280 | 53.64 |
| | Male | 242 | 46.36 |

**Figure 1**: Workflow chart of the gene model construction.
Figure 2: Continued.
identified (Figure 2(c)). The risk score analysis of the 14 DEGs was conducted to calculate the risk score for each patient. The risk score formula for our model was presented in Table 2 (Risk score = 0.16848 * C1QTNF6 + 0.15360 * ERO1A + 0.16691 * MELTF – 0.17626 * ITGB1 – DT + 0.08354 * RGS20 + 0.12733 * FETUB + 0.05565 * NTSR1 – 0.11380 * LINC02178 – 0.14829 * AC034223.2 + 0.22684 * LINC01312 + 0.18560 * AL353746.1 + 0.27908 * AC034223.1 + 0.38905 * DRAXINP1 + 0.21420 * LINC02310). Of these 14 genes, all were associated with high risk (Figure 2(c)).

3.3. The Development of the 14-Gene Prognostic Model. We divided the patients into high-risk and low-risk groups according to the median risk score (value = 0.89) by calculating the expression levels of the 14 DEGs in each patient. The log-rank test was used to determine the survival differences. As depicted in Figure 3(a), Kaplan Meier curves showed that the high-risk group was correlated with poor prognosis \( (p = 7e^{-16}) \). ROC curves indicated that the AUC of the 14-gene signature was 0.769 (Figure 3(b)), which proved that the 14-gene signature had a high specificity and sensitivity in predicting the OS of LUAD patients.

3.4. The 14-DEG Signature Independence from Conventional Clinical Factors. According to multivariate Cox regression analysis, we demonstrated that the 14-DEG signature risk score exhibited an independent predictive ability from other clinical factors \( (p = 7e^{-16}) \), shown in Figure 3(a)). Meanwhile, we found that TNM stage was an independent factor for predicting the OS of LUAD patients \( (p < 0.001) \) (Figure 4(a)). Therefore, stratification analysis was further performed to examine whether the 14-gene signature could provide predicted value for patients within the same TNM stage. Because the sample numbers in stage IV were too small to draw any reliable conclusions \( (n = 26) \), stratification analysis was carried out only in stage I, II, and III patients. Log-rank test for patients in stage I demonstrated that the 14-DEG signature could distinguish patients with significantly different survival time \( (p = 0.00018) \), Figure 4(b)). Similar predictive outcome of the 14-DEG signature was achieved in stage II \( (p = 1e^{-05}) \) and III \( (p = 9e^{-05}) \) patients (Figures 4(c) and 4(d)). Besides, distinct expression of DEGs between different clinicopathological stage samples in Figure 4(e) showed that the DEG expression was positively related to clinicopathological stage. Altogether, these results manifested that the prognostic capability of the 14-DEG signature was independent from conventional clinical factors for predicting survival of LUAD patients.

3.5. Functional Enrichment Analysis of Biological Processes and Pathways Correlated with the Prognostic DEGs in LUAD. The biological functions and pathway analyses were conducted using R package clusterProfiler. The results showed that DEGs were enriched in 181 GO biological process (BP), 10 cellular component (CC), and 14 molecular function (MF) terms. The GO categories of GO: 0051209–release of sequestered calcium ion into cytosol (BP), GO: 0005788–endoplasmic reticulum lumen (CC) and GO: 0008191–metalloendopeptidase inhibitor activity (MF) were mainly clustered, respectively (Figure 5(a)). The top 10 GO terms were shown in Table 3. The DEGs were enriched in three KEGG pathways which mainly focused on tumor metabolism, including hsa05110: vibrio cholerae infection, hsa04141: protein processing in endoplasmic reticulum, and hsa04020: calcium signaling pathway (Table 4, Figure 5(b)).

4. Discussion

NSCLC is a global health threat with high morbidity and mortality, up to 0.6 and 0.1 percent, respectively [11]. LUAD accounts for more than 40% of the lung cancer patients, showing its predominance among NSCLC. On account of the heterogeneity, conventional prognostic systems such as TNM stage sometimes exhibited predicting deficiency for risk stratification and clinical outcome estimations. Therefore, considerable outcomes are in urgent need in recent...
decades to develop efficient prognostic signatures to promote the prediction of LUAD patient survival.

Increasing evidences suggest that DEGs play indispensable and important roles in the tumorigenesis, TNM staging, and progression of lung cancer. Although several researches have identified a number of DEGs with prognostic value in NSCLC, especially in LUSC [10, 11], few studies have concentrated on and analyzed the DEG expression specifically in LUAD. Moreover, because LUAD and LUSC are vastly distinct diseases at the molecular, pathological classification and clinical level, such as distinct driver genetic changes, response to chemotherapy, or targeted therapy [4, 5], single-gene expression models are insufficient for accurate prediction of LUAD outcomes. Therefore, we focused on the molecular prognostic DEG signature patterns in LUAD.

In this study, 14-DEG signature related to overall survival of LUAD patients was identified. By means of univariate Cox regression analysis and stepwise multivariate Cox regression analysis, a novel 14-gene (C1QTNF6, ERO1A, MELTF, ITGB1-DT, RGS20, FETUB, NTSR1, LINC02178, Table 2: 14-DEG risk score model.

| DEGs      | Coef  | Exp (coef) | Se (coef) | z   | Univariate p value | Multivariate p value |
|----------|-------|------------|-----------|-----|--------------------|----------------------|
| C1QTNF6  | 0.168 | 1.18351    | 0.0848    | 1.987 | 3.230E-08          | 4.694E-02            |
| ERO1A    | 0.154 | 1.16603    | 0.10023   | 1.532 | 2.970E-08          | 1.254E-01            |
| MELTF    | 0.167 | 1.18164    | 0.05823   | 2.867 | 6.080E-07          | 4.150E-03            |
| ITGB1-DT | -0.176| 0.8384     | 0.06004   | -2.936| 2.230E-07          | 3.325E-03            |
| RGS20    | 0.084 | 1.08713    | 0.0497    | 1.681 | 2.030E-07          | 9.280E-02            |
| FETUB    | 0.127 | 1.13579    | 0.04674   | 2.724 | 5.180E-07          | 6.448E-03            |
| NTSR1    | 0.056 | 1.05723    | 0.03601   | 1.545 | 9.590E-07          | 1.223E-01            |
| LINC02178| -0.114| 0.89244    | 0.06063   | -1.877| 3.630E-09          | 6.052E-02            |
| AC034223.2| -0.148| 0.86218    | 0.09964   | -1.488| 4.450E-07          | 1.367E-01            |
| LINC01312| 0.227 | 1.25463    | 0.06224   | 3.645 | 8.990E-09          | 2.680E-04            |
| AL353746.1| 0.186 | 1.20394    | 0.04763   | 3.896 | 1.750E-09          | 9.760E-05            |
| AC034223.1| 0.279 | 1.32191    | 0.11378   | 2.453 | 2.580E-09          | 1.417E-02            |
| DRAXINP1 | 0.389 | 1.47558    | 0.09525   | 4.085 | 1.600E-08          | 4.410E-05            |
| LINC02310| 0.214 | 1.23888    | 0.08501   | 2.52  | 1.110E-09          | 1.174E-02            |

Coef: coefficient.

Figure 3: Kaplan-Meier and ROC curves for the 14-DEG signature. (a) Differences between the high-risk (n = 252) and low-risk (n = 252) groups were determined by the log-rank test (p = 7e−16). Five-year overall survival was 21.1% (95% CI: 14.19%-31.4%) and 60.1% (95% CI:50.7%-71.2%) for the high-risk and low-risk groups, respectively. (b) ROC curves indicated that the area under receiver operating characteristic of 14-DEG model was 0.769.
Stage
Risk Score
Stage I Stage II Stage III Stage IV
0 2 4 6 8 10

(a)
Stage II
Survival curve ($p = 1\times 10^{-5}$)

(b)
Stage III
Survival curve ($p = 9\times 10^{-5}$)

(c)
(d)

Figure 4: Continued.
AC034223.2, LINC01312, AL353746.1, AC034223.1, DRAXINP1, and LINC02310) prognostic signature was established and validated to demonstrate high specificity and sensitivity in predicting the overall survival time of LUAD patients. We calculated the RiskScore of each patient through the formula and the expression of selected DEGs. The patients were divided into high- and low-risk group by the median RiskScore value = 0.89; then, we obtained the survival curve according to the survival rate of all LUAD patients. To our knowledge, C1QTNF6 has been recently identified as a novel biomarker exacerbating the outcome of lung adenocarcinoma patients [15]. Combined expression of protein disulfide isomerase and endoplasmic reticulum oxidoreductin 1-α (ERO1A) is a poor prognostic marker for non-small-cell lung cancer [16]. Level of melanotransferrin (MELTF) in tissue and sera serves as a prognostic marker of gastric cancer. Patients with high serum MELTF levels had poor prognosis [17]. It was demonstrated that ITGA5 and ITGB1 are prognostic in non-small-cell lung cancer by integrin and gene network analysis [18]. Regulator of G protein signaling 20 (RGS20) was identified as molecular marker for LUAD for its exceptionally related. Moreover, gene MELTF, AC034223.2, and AC034223.1 were firstly identified related to LUAD in our study.

In a previous clinical study, NTSR1 overexpression was applied to predict a poor prognosis for 5-year OS in a stage I lung adenocarcinomas population treated by surgery alone [22]. Besides, LINC02178, LINC01312, AL353746.1, DRAXINP1, and LINC02310 were identified as the prognostic markers and prediction of the survival of LUAD by genome-scale analysis [23]. Among the identified 14 genes in this study, all were associated with high risk, indicating that the expression of these genes was positively related. Therefore, it is convincing to infer that the fourteen prognostic DEGs participate in the progression of LUAD in these LUAD-related biological pathways. However, further
Figure 5: Identification of the DEGs related biological processes and pathways. (a) The functional enrichment analysis of Gene ontology (GO) terms. (b) KEGG pathways for DEGs.
Experimental studies are needed to confirm the functions of these DEGs. Our findings provide insights into prognosis-related genes of LUAD and may have a positive clinical capacity for prognosis prediction and target therapy in LUAD management.

5. Conclusions

In summary, this study identified a novel 14-DEG prognostic signature which could predict the survival risk of LUAD patients. The signature exhibited independent prognostic capacity of clinicopathological factors and could predict survival outcomes of LUAD patients within the same TNM stage. This signature could be utilized to identify patients with high-risk scores who may be further desperate for more effective and individualized therapy. It could not only serve as a novel potential biomarker for the survival risk stratification of LUAD patient but also provide us a better understanding of molecular mechanisms involved in the development of LUAD. However, further molecular investigations, such as exploring the underlying mechanisms of these DEGs in LUAD development and performing

| ONTOLOGY | ID | Description | p value | Count |
|----------|----|-------------|---------|-------|
| BP       | GO:0051209 | Release of sequestered calcium ion into cytosol | 0.000383 | 2 |
| BP       | GO:0051283 | Negative regulation of sequestering of calcium ion | 0.00039 | 2 |
| BP       | GO:0051282 | Regulation of sequestering of calcium ion | 0.000403 | 2 |
| BP       | GO:0051208 | Sequestering of calcium ion | 0.000423 | 2 |
| BP       | GO:0097553 | Calcium ion transmembrane import into cytosol | 0.000539 | 2 |
| BP       | GO:0060402 | Calcium ion transport into cytosol | 0.000686 | 2 |
| BP       | GO:0060401 | Cytosolic calcium ion transport | 0.000869 | 2 |
| BP       | GO:0051651 | Maintenance of location in cell | 0.001275 | 2 |
| BP       | GO:009266 | Response to temperature stimulus | 0.001482 | 2 |
| BP       | GO:0051604 | Protein maturation | 0.002331 | 2 |
| CC       | GO:0005788 | Endoplasmic reticulum lumen | 0.003556 | 2 |
| CC       | GO:0032280 | Symmetric synapse | 0.003676 | 1 |
| CC       | GO:0043198 | Dendritic shaft | 0.011602 | 1 |
| CC       | GO:0043195 | Terminal Bouton | 0.017058 | 1 |
| CC       | GO:0046658 | Anchored component of plasma membrane | 0.018268 | 1 |
| CC       | GO:0005581 | Collagen trimer | 0.026397 | 1 |
| CC       | GO:0043679 | Axon terminus | 0.039227 | 1 |
| CC       | GO:0044306 | Neuron projection terminus | 0.044852 | 1 |
| CC       | GO:0043204 | Perikaryon | 0.046917 | 1 |
| CC       | GO:0009898 | Cytoplasmic side of plasma membrane | 0.049273 | 1 |
| MF       | GO:0008191 | Metalloendopeptidase inhibitor activity | 0.00522 | 1 |
| MF       | GO:0003756 | Protein disulfide isomerase activity | 0.006197 | 1 |
| MF       | GO:0016864 | Intramolecular oxidoreductase activity, transposing S-S bonds | 0.006197 | 1 |
| MF       | GO:0015035 | Protein disulfide oxidoreductase activity | 0.007172 | 1 |
| MF       | GO:0015036 | Disulfide oxidoreductase activity | 0.013332 | 1 |
| MF       | GO:0008188 | Neuropeptide receptor activity | 0.014624 | 1 |
| MF       | GO:0016860 | Intramolecular oxidoreductase activity | 0.016238 | 1 |
| MF       | GO:0004869 | Cysteine-type endopeptidase inhibitor activity | 0.019138 | 1 |
| MF       | GO:0016667 | Oxidoreductase activity, acting on a sulfur group of donors | 0.019138 | 1 |
| MF       | GO:0047485 | Protein N-terminus binding | 0.034481 | 1 |

| ID         | Description                                  | p value | Count |
|------------|----------------------------------------------|---------|-------|
| hsa05110   | Vibrio cholerae infection                     | 0.012345| 1     |
| hsa04141   | Protein processing in endoplasmic reticulum   | 0.041902| 1     |
| hsa04020   | Calcium signaling pathway                     | 0.049161| 1     |
independent cohorts of large sample sizes from institutions across the country or world, are necessary to confirm accuracy and stability for the prediction signature.

Data Availability
The data used to support the findings of this study are included within the article.

Conflicts of Interest
The authors declare that there is no conflict of interest regarding the publication of this paper.

Authors’ Contributions
Jie Liu, Shiqiang Hou, Jinyi Wang and Zhengjun Chai contributed equally to this work.

Acknowledgments
The study was supported by the National Key Research and Development Program of China (2017YFA0105600), the National Natural Science Foundation of China (81770094 and 81670458), the Shanghai Municipal Health and Family Planning Commission (ZY3-LCPT-2-1003 and 2014ZYJB0502), Key Discipline Project of Pudong Health Bureau of Shanghai (PWZsk2017-01), and the Science and Technology Commission of Shanghai Municipality (17431906600).

References
[1] K. W. Bi, X. G. Wei, X. X. Qin, and B. Li, “BTK has potential to be a prognostic factor for lung adenocarcinoma and an indicator for tumor microenvironment remodeling: a study based on TCGA data mining,” Frontiers in Oncology, vol. 10, p. 424, 2020.
[2] M. J. Duffy and K. O’Byrne, “Tissue and blood biomarkers in lung cancer: a review,” Advances in Clinical Chemistry, vol. 86, pp. 1–21, 2018.
[3] R. Yan, Y. Jiang, B. Lai, Y. Lin, and J. Wen, “The positive feedback loop FOXO3/CASC11/miR-498 promotes the tumorigenesis of non-small cell lung cancer,” Biochemical and Biophysical Research Communications, vol. 519, no. 3, pp. 518–524, 2019.
[4] E. K. Kleczko, J. W. Kwak, E. L. Schenk, and R. A. Nemenoff, “Targeting the complement pathway as a therapeutic strategy in lung cancer,” Frontiers in Immunology, vol. 10, p. 954, 2019.
[5] V. Relli, M. Trerotola, E. Guerra, and S. Alberti, “Abandoning the notion of non-small cell lung cancer,” Trends in Molecular Medicine, vol. 25, no. 7, pp. 585–594, 2019.
[6] S. Zuo, M. Wei, H. Zhang et al., “A robust six-gene prognostic signature for prediction of both disease-free and overall survival in non-small cell lung cancer,” Journal of Translational Medicine, vol. 17, no. 1, p. 152, 2019.
[7] C. Mascaux, M. Angelova, A. Vasaturro et al., “Immune evasion before tumour invasion in early lung squamous carcinogenesis,” Nature, vol. 571, no. 7766, pp. 570–575, 2019.
[8] A. Prelaj, R. Tay, R. Ferrara, N. Chaput, B. Besse, and R. Califano, “Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer,” European Journal of Cancer, vol. 106, pp. 144–159, 2019.
[9] D. Luo, B. Deng, M. Weng, Z. Luo, and X. Nie, “A prognostic 4-lncRNA expression signature for lung squamous cell carcinoma,” Artif Cells Nanomed Biotechnol., vol. 46, no. 6, pp. 1207–1214, 2018.
[10] J. R. Kratz, M. J. Mann, and D. M. Jablons, “International trial of adjuvant therapy in high risk stage I non-squamous cell carcinoma identified by a 14-gene prognostic signature,” Transl Lung Cancer Res., vol. 2, no. 3, pp. 222–225, 2013.
[11] J. Li, J. Wang, Y. Chen, L. Yang, and S. Chen, “A prognostic 4-gene expression signature for squamous cell lung carcinoma,” Journal of Cellular Physiology, vol. 232, no. 12, pp. 3702–3713, 2017.
[12] C.-Q. Zhu, D. Strumpf, C.-Y. Li et al., “Prognostic gene expression signature for squamous cell carcinoma of lung,” Clinical Cancer Research, vol. 16, no. 20, pp. 5038–5047, 2010.
[13] M. D. Robinson, D. J. McCarthy, and G. K. Smyth, “edgeR: a bioconductor package for differential expression analysis of digital gene expression data,” Bioinformatics, vol. 26, no. 1, pp. 139–140, 2010.
[14] P. J. Heagerty, T. Lumley, and M. S. Pepe, “Time-dependent ROC curves for censored survival data and a diagnostic marker,” Biometrics, vol. 56, no. 2, pp. 337–344, 2000.
[15] M. Han, B. Wang, M. Zhu, and Y. Zhang, “C1QTNF6 as a novel biomarker regulates cellular behaviors in A549 cells and exacerbates the outcome of lung adenocarcinoma patients,” In Vitro Cellular & Developmental Biology. Animal, vol. 55, no. 8, pp. 614–621, 2019.
[16] K. M. Kim, A. R. An, H. S. Park et al., “Combined expression of protein disulfide isomerase and endoplasmic reticulum oxidoreductin 1-a is a poor prognostic marker for non-small cell lung cancer,” Oncology Letters, vol. 16, no. 5, pp. 5753–5760, 2018.
[17] K. Sawaki, M. Kanda, S. Umeda et al., “Level of melanotransferrin in tissue and sera serves as a prognostic marker of gastric cancer,” Anticancer Research, vol. 39, no. 11, pp. 6125–6133, 2019.
[18] W. Zheng, C. Jiang, and R. Li, “Integrin and gene network analysis reveals that ITGA5 and ITGB1 are prognostic in non-small-cell lung cancer,” Oncotargets and Therapy, vol. 9, pp. 2317–2327, 2016.
[19] J. Zhao, W. Cheng, X. He et al., “Construction of a specific SVM classifier and identification of molecular markers for lung adenocarcinoma based on IncRNA-miRNA-mRNA network,” Oncotargets and Therapy, vol. Volume 11, pp. 3129–3140, 2018.
[20] L. Yang, M. M. Lee, M. M. Leung, and Y. H. Wong, “Regulator of G protein signaling 20 enhances cancer cell aggregation, migration, invasion and adhesion,” Cellular Signalling, vol. 28, no. 11, pp. 1663–1672, 2016.
[21] W.-q. Diao, N. Shen, Y.-p. Du et al., “Fetu-in-B (FETUB): a plasma biomarker candidate related to the severity of lung function in COPD,” Scientific Reports, vol. 6, no. 1, article 30045, 2016.
[22] M. Younes, Z. Wu, S. Dupouy et al., “Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 overexpression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib,” Oncotarget, vol. 5, no. 18, pp. 8252–8269, 2014.
[23] Y. Y. Li, C. Yang, P. Zhou, S. Zhang, Y. Yao, and D. Li, “Genome-scale analysis to identify prognostic markers and predict the survival of lung adenocarcinoma,” Journal of Cellular Biochemistry, vol. 119, no. 11, pp. 8909–8921, 2018.